Cardiovascular Advances in Research and Opportunities Legacy Act

Bill: 117-hr-1193
Sponsor: full_name: Rep. Barr, Andy [R-KY-6]
Introduced: 2021-02-22
Policy area: Health
Subjects: Advanced technology and technological innovations

Cardiovascular and respiratory health

Government information and archives

Health information and medical records

Health programs administration and funding

Health promotion and preventive care

Health technology, devices, supplies

Medical research

Medical tests and diagnostic methods

Photography and imaging

Research administration and funding
Latest action: action_date: 2022-12-20
text: Became Public Law No: 117-244.

Summaries:
action_date: 2021-02-22
action_desc: Introduced in House
text: <p><b>Cardiovascular Advances in Research and Opportunities Legacy Act</b></p> <p>This bill expands research on valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.</p> <p>The National Institutes of Health must consult with the National Heart, Lung, and Blood Institute to conduct or support research on the disease, including on mitral valve prolapse. This occurs when the valve between the chambers of the left side of the heart seals improperly.</p> <p>The Centers for Disease Control and Prevention (CDC) must develop best practices to treat valvular heart disease. The CDC may also carry out other projects to increase awareness of and reduce deaths from the disease.</p>

action_date: 2021-12-08
action_desc: Passed House
text: <p><b>Cardiovascular Advances in Research and Opportunities Legacy Act</b></p> <p>This bill expands research on valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.</p> <p>The National Institutes of Health must consult with the National Heart, Lung, and Blood Institute to conduct or support research on the disease, including on mitral valve prolapse. This occurs when the valve between the chambers of the left side of the heart seals improperly.</p> <p>The Centers for Disease Control and Prevention (CDC) must develop best practices to treat valvular heart disease. The CDC may also carry out other projects to increase awareness of and reduce deaths from the disease.</p>

action_date: 2022-07-12
action_desc: Reported to Senate
text: <p><b>Cardiovascular Advances in Research and Opportunities Legacy Act</b></p> <p>This bill addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.</p> <p>The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.</p> <p>The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.</p>

action_date: 2022-12-01
action_desc: Passed Senate
text: <p><b>Cardiovascular Advances in Research and Opportunities Legacy Act</b></p> <p>This bill addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.</p> <p>The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.</p> <p>The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.</p>

action_date: 2022-12-05
action_desc: House agreed to Senate amendment
text: <p><b>Cardiovascular Advances in Research and Opportunities Legacy Act</b></p> <p>This bill addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.</p> <p>The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.</p> <p>The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.</p>

action_date: 2022-12-20
action_desc: Public Law
text: <p><b>Cardiovascular Advances in Research and Opportunities Legacy Act</b></p> <p>This act addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.</p> <p>The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.</p> <p>The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.</p>

tv_txt: I 117th CONGRESS 1st Session H. R. 1193 IN THE HOUSE OF REPRESENTATIVES February 22, 2021 Mr. Barr introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, shall establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act . 2. Grants for valvular heart disease research Subpart 2 of part C of title IV of the Public Health Service Act ( 42 U.S.C. 285b et seq.) is amended by inserting after section 424C ( 42 U.S.C. 285b–7c ) the following: 424D. Grants for valvular heart disease research (a) In general The Director of the National Institutes of Health, in consultation with the Director of the Institute, shall support or conduct research regarding valvular heart disease. (b) Support guidelines The distribution of funding authorized in subsection (a) may be used to pursue the following outcomes— (1) using precision medicine and advanced technological imaging to generate data on individuals with valvular heart disease; (2) identifying and developing a cohort of individuals with valvular heart disease and available data; (3) corroborating data generated through clinical trials to develop a prediction model to distinguish individuals at high risk for sudden cardiac arrest or sudden cardiac death from valvular heart disease; or (4) for other outcomes needed to acquire necessary data on valvular heart disease. (c) Mitral valve prolapse workshop Not later than one year after the date of the enactment of this section, the Director of the Institute shall convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop prescriptive guidelines for treatment of individuals with mitral valve prolapse. (d) Authorization of appropriations For the purpose of carrying out this section, there is authorized to be appropriated $20,000,000 for each of fiscal years 2022 through 2026. . 3. Programs of centers for disease control and prevention Part J of title III of the Public Health Service Act ( 42 U.S.C. 2 et seq.) is amended by inserting after section 393 the following section: 393A. Prevention of sudden cardiac death as a result of valvular heart disease (a) In general The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may carry out projects to increase education, awareness or diagnosis of valvular heart disease and to reduce the incidence of sudden cardiac death caused by valvular heart disease. Such projects may be carried out by the Secretary directly or through awards of grants or contracts to public or nonprofit private entities. The Secretary may directly (or through such awards) provide technical assistance with respect to the planning, development, and operation of such projects. (b) Certain activities Projects carried out under subsection (a) may include— (1) the implementation of public information and education programs for— (A) the prevention of sudden cardiac death from valvular heart disease; (B) broadening the awareness of the public concerning the risk factors for, the symptoms of, and the public health consequences of valvular heart disease; and (C) increasing screening, detection, and diagnosis of valvular heart disease; and (2) surveillance of out of hospital cardiac arrests to improve patient outcomes. (c) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to subsection (a), give priority to entities seeking to carry out projects that target populations most impacted by valvular heart disease. (d) Coordination of activities The Secretary shall ensure that activities under this section are coordinated, as appropriate, with other agencies of the Public Health Service that carry out activities regarding valvular heart disease. (e) Best practices The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall— (1) collect and analyze the findings of research conducted with respect to valvular heart disease; and (2) taking into account such findings, publish on the website of the Centers for Disease Control and Prevention best practices for physicians and other health care providers who provide care to individuals with valvular heart disease. (f) Authorization of appropriations For the purpose of carrying out this section, there is authorized to be appropriated such sums as may be necessary for each of fiscal years 2022 through 2026. .

tv_txt: I 117th CONGRESS 1st Session H. R. 1193 IN THE HOUSE OF REPRESENTATIVES AN ACT To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act . 2. Grants for valvular heart disease research Subpart 2 of part C of title IV of the Public Health Service Act ( 42 U.S.C. 285b et seq. ) is amended by inserting after section 424C ( 42 U.S.C. 285b–7c ) the following: 424D. Grants for valvular heart disease research (a) In general The Director of the National Institutes of Health, in consultation with the Director of the Institute, shall support or conduct research regarding valvular heart disease. (b) Support guidelines The distribution of funding authorized under subsection (a) may be used to pursue the following outcomes: (1) Using precision medicine and advanced technological imaging to generate data on individuals with valvular heart disease. (2) Identifying and developing a cohort of individuals with valvular heart disease and available data. (3) Corroborating data generated through clinical trials to develop a prediction model to distinguish individuals at high risk for sudden cardiac arrest or sudden cardiac death from valvular heart disease. (4) For other outcomes needed to acquire necessary data on valvular heart disease. (c) Mitral valve prolapse workshop Not later than one year after the date of the enactment of this section, the Director of the Institute shall convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop prescriptive guidelines for treatment of individuals with mitral valve prolapse. (d) Authorization of appropriations For the purpose of carrying out this section, there is authorized to be appropriated $20,000,000 for each of fiscal years 2022 through 2026. . 3. Programs of Centers for Disease Control and Prevention Part B of title III of the Public Health Service Act ( 42 U.S.C. 243 et seq. ) is amended by inserting after section 312 the following section : 312A. Prevention of sudden cardiac death as a result of valvular heart disease (a) In general The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may carry out projects to increase education, awareness, or diagnosis of valvular heart disease and to reduce the incidence of sudden cardiac death caused by valvular heart disease. Such projects may be carried out by the Secretary directly or through awards of grants or contracts to public or nonprofit private entities. The Secretary may directly (or through such awards) provide technical assistance with respect to the planning, development, and operation of such projects. (b) Certain activities Upon availability of applicable data, projects carried out under subsection (a) may include— (1) continuing the activities at the Division for Heart Disease and Stroke Prevention, including those related to valvular heart disease; (2) broadening the awareness of the public concerning the risk factors for, the symptoms of, and the public health consequences of valvular heart disease; and (3) enhancing surveillance of out-of-hospital cardiac arrests to improve patient outcomes. (c) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to subsection (a), give priority to entities seeking to carry out projects that target populations most impacted by valvular heart disease. (d) Coordination of activities The Secretary shall ensure that activities under this section are coordinated, as appropriate, with other agencies of the Public Health Service that carry out activities regarding valvular heart disease. (e) Best practices The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall— (1) collect and analyze the findings of research conducted with respect to valvular heart disease; and (2) taking into account such findings, publish on the website of the Centers for Disease Control and Prevention best practices for physicians and other health care providers who provide care to individuals with valvular heart disease. .

Passed the House of Representatives December 8, 2021. Cheryl L. Johnson, Clerk.

tv_txt: II 117th CONGRESS 1st Session H. R. 1193 IN THE SENATE OF THE UNITED STATES December 9, 2021 Received AN ACT To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act . 2. Grants for valvular heart disease research Subpart 2 of part C of title IV of the Public Health Service Act ( 42 U.S.C. 285b et seq. ) is amended by inserting after section 424C ( 42 U.S.C. 285b–7c ) the following: 424D. Grants for valvular heart disease research (a) In general The Director of the National Institutes of Health, in consultation with the Director of the Institute, shall support or conduct research regarding valvular heart disease. (b) Support guidelines The distribution of funding authorized under subsection (a) may be used to pursue the following outcomes: (1) Using precision medicine and advanced technological imaging to generate data on individuals with valvular heart disease. (2) Identifying and developing a cohort of individuals with valvular heart disease and available data. (3) Corroborating data generated through clinical trials to develop a prediction model to distinguish individuals at high risk for sudden cardiac arrest or sudden cardiac death from valvular heart disease. (4) For other outcomes needed to acquire necessary data on valvular heart disease. (c) Mitral valve prolapse workshop Not later than one year after the date of the enactment of this section, the Director of the Institute shall convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop prescriptive guidelines for treatment of individuals with mitral valve prolapse. (d) Authorization of appropriations For the purpose of carrying out this section, there is authorized to be appropriated $20,000,000 for each of fiscal years 2022 through 2026. . 3. Programs of Centers for Disease Control and Prevention Part B of title III of the Public Health Service Act ( 42 U.S.C. 243 et seq. ) is amended by inserting after section 312 the following section : 312A. Prevention of sudden cardiac death as a result of valvular heart disease (a) In general The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may carry out projects to increase education, awareness, or diagnosis of valvular heart disease and to reduce the incidence of sudden cardiac death caused by valvular heart disease. Such projects may be carried out by the Secretary directly or through awards of grants or contracts to public or nonprofit private entities. The Secretary may directly (or through such awards) provide technical assistance with respect to the planning, development, and operation of such projects. (b) Certain activities Upon availability of applicable data, projects carried out under subsection (a) may include— (1) continuing the activities at the Division for Heart Disease and Stroke Prevention, including those related to valvular heart disease; (2) broadening the awareness of the public concerning the risk factors for, the symptoms of, and the public health consequences of valvular heart disease; and (3) enhancing surveillance of out-of-hospital cardiac arrests to improve patient outcomes. (c) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to subsection (a), give priority to entities seeking to carry out projects that target populations most impacted by valvular heart disease. (d) Coordination of activities The Secretary shall ensure that activities under this section are coordinated, as appropriate, with other agencies of the Public Health Service that carry out activities regarding valvular heart disease. (e) Best practices The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall— (1) collect and analyze the findings of research conducted with respect to valvular heart disease; and (2) taking into account such findings, publish on the website of the Centers for Disease Control and Prevention best practices for physicians and other health care providers who provide care to individuals with valvular heart disease. .

Passed the House of Representatives December 8, 2021. Cheryl L. Johnson, Clerk.

tv_txt: IB Union Calendar No. 153 117th CONGRESS 1st Session H. R. 1193 [Report No. 117–212] IN THE HOUSE OF REPRESENTATIVES February 22, 2021 Mr. Barr introduced the following bill; which was referred to the Committee on Energy and Commerce December 8, 2021 Additional sponsors: Miss Rice of New York , Mr. Fitzpatrick , Mr. Guthrie , Mr. Kilmer , Mr. Rodney Davis of Illinois , Mr. Smith of New Jersey , Mr. Timmons , Mrs. Wagner , Mr. Huizenga , Mr. Arrington , Mr. McHenry , Mr. Taylor , Mr. Rogers of Kentucky , Mr. Comer , Mr. Gooden of Texas , Mr. Davidson , Mr. Rutherford , Mr. Smucker , Mr. Joyce of Pennsylvania , Mr. Meeks , Mr. Ferguson , Mr. Krishnamoorthi , Mr. Reed , Mr. Bost , Mr. Newhouse , Mr. Palazzo , Mr. Austin Scott of Georgia , Mr. Diaz-Balart , Mr. Murphy of North Carolina , Mr. Joyce of Ohio , Mr. Yarmuth , Ms. Tenney , Mr. Loudermilk , Mr. Stauber , Mr. Tonko , Mr. Welch , Mr. Fortenberry , Mr. Stivers , Mr. Bucshon , Mr. Valadao , Mr. Peters , Mr. Rose , Mr. Gonzalez of Ohio , Mr. Long , Mr. Carter of Georgia , Mr. Van Drew , Mr. Kinzinger , Mr. Norman , Mr. Wenstrup , Mr. Jackson , Mr. Young , Mr. Perlmutter , Ms. Dean , Mr. Meuser , Mr. Suozzi , Mr. McCaul , Mr. Pence , Mr. Wittman , Mrs. Carolyn B. Maloney of New York , Mr. Womack , Mr. Luetkemeyer , Mr. Simpson , Ms. Stefanik , Mr. Hill , Mr. Kildee , Mr. Duncan , Mr. Dunn , Mrs. Beatty , Ms. DeGette , Mr. Vargas , Mr. Gottheimer , Mr. McKinley , Mr. Fleischmann , Mr. Zeldin , Mr. Morelle , Mr. Butterfield , Mr. Gallagher , Mr. Bishop of Georgia , Ms. Barragán , Ms. Kuster , Mr. Panetta , Mrs. Miller of West Virginia , Mr. Garbarino , Mr. Mooney , Mr. Bacon , Mr. Smith of Missouri , Mrs. Torres of California , Mr. Calvert , Mr. Aderholt , Mr. LaTurner , Mr. LaHood , Mr. Posey , Mr. Babin , Mr. Hollingsworth , Ms. Waters , Mr. LaMalfa , Mr. Steil , Ms. Garcia of Texas , Mr. Green of Texas , Mrs. Lesko , Mr. Cicilline , Ms. Jackson Lee , Ms. Herrera Beutler , Mr. Bera , Mr. Banks , Mr. Trone , Mrs. McBath , Mrs. Luria , Mr. Higgins of Louisiana , Mr. Williams of Texas , Mr. Lucas , Mr. Kustoff , Mr. Rice of South Carolina , Mr. Mast , Mr. Brendan F. Boyle of Pennsylvania , Mr. Meijer , Mrs. Murphy of Florida , Mr. Moore of Utah , Mr. Cartwright , Mr. Kim of New Jersey , Mr. Quigley , Ms. Stevens , Mr. David Scott of Georgia , Ms. Blunt Rochester , Mr. Balderson , Mr. Norcross , Mr. Lamborn , Mr. Bilirakis , Mr. Cole , Mrs. Bice of Oklahoma , Mr. Curtis , Ms. Ross , Mr. Armstrong , Mr. Sessions , Mr. Harder of California , Mr. Delgado , Mr. Graves of Missouri , Mr. Vela , Mrs. Kim of California , Mr. Hudson , Ms. Craig , Ms. Schrier , Mr. Mann , Mr. Emmer , Mr. Johnson of Ohio , Mrs. Hinson , Mr. Allen , Ms. Salazar , Mr. C. Scott Franklin of Florida , Mr. Khanna , Mrs. Miller-Meeks , Mr. Johnson of Louisiana , Mr. Cleaver , Ms. Williams of Georgia , Ms. Matsui , Mr. Pappas , Mr. Michael F. Doyle of Pennsylvania , Mr. Ruiz , Mr. Steube , Mrs. Walorski , Mr. Schneider , Mr. O'Halleran , Mr. Mullin , Mr. Lieu , Mr. Lamb , Mr. Burgess , Mr. Auchincloss , Mr. Amodei , Ms. Stansbury , Mr. Lynch , Ms. Cheney , Ms. Roybal-Allard , Mrs. Fletcher , Mrs. Lee of Nevada , Ms. Malliotakis , Mr. Soto , Mr. Guest , Mr. Rush , Mr. Walberg , Ms. Letlow , Ms. Wexton , Mr. Crow , and Mr. Casten December 8, 2021 Reported with amendments, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed Strike out all after the enacting clause and insert the part printed in italic For text of introduced bill, see copy of bill as introduced on February 22, 2021 A BILL To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, shall establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act . 2. Grants for valvular heart disease research Subpart 2 of part C of title IV of the Public Health Service Act ( 42 U.S.C. 285b et seq. ) is amended by inserting after section 424C ( 42 U.S.C. 285b–7c ) the following: 424D. Grants for valvular heart disease research (a) In general The Director of the National Institutes of Health, in consultation with the Director of the Institute, shall support or conduct research regarding valvular heart disease. (b) Support guidelines The distribution of funding authorized under subsection (a) may be used to pursue the following outcomes: (1) Using precision medicine and advanced technological imaging to generate data on individuals with valvular heart disease. (2) Identifying and developing a cohort of individuals with valvular heart disease and available data. (3) Corroborating data generated through clinical trials to develop a prediction model to distinguish individuals at high risk for sudden cardiac arrest or sudden cardiac death from valvular heart disease. (4) For other outcomes needed to acquire necessary data on valvular heart disease. (c) Mitral valve prolapse workshop Not later than one year after the date of the enactment of this section, the Director of the Institute shall convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop prescriptive guidelines for treatment of individuals with mitral valve prolapse. (d) Authorization of appropriations For the purpose of carrying out this section, there is authorized to be appropriated $20,000,000 for each of fiscal years 2022 through 2026. . 3. Programs of Centers for Disease Control and Prevention Part B of title III of the Public Health Service Act ( 42 U.S.C. 243 et seq. ) is amended by inserting after section 312 the following section : 312A. Prevention of sudden cardiac death as a result of valvular heart disease (a) In general The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may carry out projects to increase education, awareness, or diagnosis of valvular heart disease and to reduce the incidence of sudden cardiac death caused by valvular heart disease. Such projects may be carried out by the Secretary directly or through awards of grants or contracts to public or nonprofit private entities. The Secretary may directly (or through such awards) provide technical assistance with respect to the planning, development, and operation of such projects. (b) Certain activities Upon availability of applicable data, projects carried out under subsection (a) may include— (1) continuing the activities at the Division for Heart Disease and Stroke Prevention, including those related to valvular heart disease; (2) broadening the awareness of the public concerning the risk factors for, the symptoms of, and the public health consequences of valvular heart disease; and (3) enhancing surveillance of out-of-hospital cardiac arrests to improve patient outcomes. (c) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to subsection (a), give priority to entities seeking to carry out projects that target populations most impacted by valvular heart disease. (d) Coordination of activities The Secretary shall ensure that activities under this section are coordinated, as appropriate, with other agencies of the Public Health Service that carry out activities regarding valvular heart disease. (e) Best practices The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall— (1) collect and analyze the findings of research conducted with respect to valvular heart disease; and (2) taking into account such findings, publish on the website of the Centers for Disease Control and Prevention best practices for physicians and other health care providers who provide care to individuals with valvular heart disease. .

Amend the title so as to read: A bill to amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes. .

December 8, 2021 Reported with amendments, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed

tv_txt: IIB 117th CONGRESS 2d Session H. R. 1193 IN THE SENATE OF THE UNITED STATES December 9, 2021 Received May 25, 2022 Read twice and referred to the Committee on Health, Education, Labor, and Pensions AN ACT To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act . 2. Grants for valvular heart disease research Subpart 2 of part C of title IV of the Public Health Service Act ( 42 U.S.C. 285b et seq. ) is amended by inserting after section 424C ( 42 U.S.C. 285b–7c ) the following: 424D. Grants for valvular heart disease research (a) In general The Director of the National Institutes of Health, in consultation with the Director of the Institute, shall support or conduct research regarding valvular heart disease. (b) Support guidelines The distribution of funding authorized under subsection (a) may be used to pursue the following outcomes: (1) Using precision medicine and advanced technological imaging to generate data on individuals with valvular heart disease. (2) Identifying and developing a cohort of individuals with valvular heart disease and available data. (3) Corroborating data generated through clinical trials to develop a prediction model to distinguish individuals at high risk for sudden cardiac arrest or sudden cardiac death from valvular heart disease. (4) For other outcomes needed to acquire necessary data on valvular heart disease. (c) Mitral valve prolapse workshop Not later than one year after the date of the enactment of this section, the Director of the Institute shall convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop prescriptive guidelines for treatment of individuals with mitral valve prolapse. (d) Authorization of appropriations For the purpose of carrying out this section, there is authorized to be appropriated $20,000,000 for each of fiscal years 2022 through 2026. . 3. Programs of Centers for Disease Control and Prevention Part B of title III of the Public Health Service Act ( 42 U.S.C. 243 et seq. ) is amended by inserting after section 312 the following section : 312A. Prevention of sudden cardiac death as a result of valvular heart disease (a) In general The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may carry out projects to increase education, awareness, or diagnosis of valvular heart disease and to reduce the incidence of sudden cardiac death caused by valvular heart disease. Such projects may be carried out by the Secretary directly or through awards of grants or contracts to public or nonprofit private entities. The Secretary may directly (or through such awards) provide technical assistance with respect to the planning, development, and operation of such projects. (b) Certain activities Upon availability of applicable data, projects carried out under subsection (a) may include— (1) continuing the activities at the Division for Heart Disease and Stroke Prevention, including those related to valvular heart disease; (2) broadening the awareness of the public concerning the risk factors for, the symptoms of, and the public health consequences of valvular heart disease; and (3) enhancing surveillance of out-of-hospital cardiac arrests to improve patient outcomes. (c) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to subsection (a), give priority to entities seeking to carry out projects that target populations most impacted by valvular heart disease. (d) Coordination of activities The Secretary shall ensure that activities under this section are coordinated, as appropriate, with other agencies of the Public Health Service that carry out activities regarding valvular heart disease. (e) Best practices The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall— (1) collect and analyze the findings of research conducted with respect to valvular heart disease; and (2) taking into account such findings, publish on the website of the Centers for Disease Control and Prevention best practices for physicians and other health care providers who provide care to individuals with valvular heart disease. .

Passed the House of Representatives December 8, 2021. Cheryl L. Johnson, Clerk.

tv_txt: II Calendar No. 443 117th CONGRESS 2d Session H. R. 1193 IN THE SENATE OF THE UNITED STATES December 9, 2021 Received May 25, 2022 Read twice and referred to the Committee on Health, Education, Labor, and Pensions July 12, 2022 Reported by Mrs. Murray , with an amendment Strike out all after the enacting clause and insert the part printed in italic AN ACT To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act . 2. Grants for valvular heart disease research Subpart 2 of part C of title IV of the Public Health Service Act ( 42 U.S.C. 285b et seq. ) is amended by inserting after section 424C ( 42 U.S.C. 285b–7c ) the following: 424D. Grants for valvular heart disease research (a) In general The Director of the National Institutes of Health, in consultation with the Director of the Institute, shall support or conduct research regarding valvular heart disease. (b) Support guidelines The distribution of funding authorized under subsection (a) may be used to pursue the following outcomes: (1) Using precision medicine and advanced technological imaging to generate data on individuals with valvular heart disease. (2) Identifying and developing a cohort of individuals with valvular heart disease and available data. (3) Corroborating data generated through clinical trials to develop a prediction model to distinguish individuals at high risk for sudden cardiac arrest or sudden cardiac death from valvular heart disease. (4) For other outcomes needed to acquire necessary data on valvular heart disease. (c) Mitral valve prolapse workshop Not later than one year after the date of the enactment of this section, the Director of the Institute shall convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop prescriptive guidelines for treatment of individuals with mitral valve prolapse. (d) Authorization of appropriations For the purpose of carrying out this section, there is authorized to be appropriated $20,000,000 for each of fiscal years 2022 through 2026. . 3. Programs of Centers for Disease Control and Prevention Part B of title III of the Public Health Service Act ( 42 U.S.C. 243 et seq. ) is amended by inserting after section 312 the following section : 312A. Prevention of sudden cardiac death as a result of valvular heart disease (a) In general The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may carry out projects to increase education, awareness, or diagnosis of valvular heart disease and to reduce the incidence of sudden cardiac death caused by valvular heart disease. Such projects may be carried out by the Secretary directly or through awards of grants or contracts to public or nonprofit private entities. The Secretary may directly (or through such awards) provide technical assistance with respect to the planning, development, and operation of such projects. (b) Certain activities Upon availability of applicable data, projects carried out under subsection (a) may include— (1) continuing the activities at the Division for Heart Disease and Stroke Prevention, including those related to valvular heart disease; (2) broadening the awareness of the public concerning the risk factors for, the symptoms of, and the public health consequences of valvular heart disease; and (3) enhancing surveillance of out-of-hospital cardiac arrests to improve patient outcomes. (c) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to subsection (a), give priority to entities seeking to carry out projects that target populations most impacted by valvular heart disease. (d) Coordination of activities The Secretary shall ensure that activities under this section are coordinated, as appropriate, with other agencies of the Public Health Service that carry out activities regarding valvular heart disease. (e) Best practices The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall— (1) collect and analyze the findings of research conducted with respect to valvular heart disease; and (2) taking into account such findings, publish on the website of the Centers for Disease Control and Prevention best practices for physicians and other health care providers who provide care to individuals with valvular heart disease. .

1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act . 2. HHS valvular heart disease activities (a) In general The Secretary of Health and Human Services (referred to in this section as the Secretary ) shall, as appropriate, continue activities related to research, education, and awareness of valvular heart diseases. (b) NIH research related to valvular heart diseases (1) In general The Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, may support or conduct research regarding valvular heart diseases. (2) Support further research In order to improve information on, and understanding of, causation and risk factors for valvular heart diseases, research conducted or supported under this subsection for such diseases may include the following: (A) Use of advanced technological imaging and other relevant methods to generate data related to valvular heart diseases. (B) Assessing potential risk factors for sudden cardiac arrest or sudden cardiac death from valvular heart diseases. (C) Other activities, as appropriate, in order to improve the availability of information on, and advance research related to, valvular heart diseases. (3) Mitral valve prolapse workshop Not later than one year after the date of enactment of this Act, the Director of the National Heart, Lung, and Blood Institute shall, as appropriate, convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop recommendations for the identification and treatment of individuals with mitral valve prolapse, including such individuals who may be at risk for sudden cardiac arrest or sudden cardiac death. (c) Prevention activities to improve awareness of sudden cardiac death as a result of valvular heart diseases (1) In general The Secretary may carry out activities to increase education and awareness of valvular heart diseases in order to reduce the incidence of sudden cardiac death caused by such diseases. The Secretary may— (A) award grants or contracts to public or nonprofit private entities to carry out activities under this subsection; and (B) may directly, or through grants or contracts, provide technical assistance with respect to such activities. (2) Certain activities Upon availability of applicable data, projects carried out under paragraph (1) may include— (A) continuing activities at the Centers for Disease Control and Prevention related to valvular heart diseases; (B) improving the awareness of the public concerning any risk factors for, the symptoms of, and the public health impact of, valvular heart diseases; and (C) improving the availability of public health data and information, as appropriate, regarding cardiac arrests related to valvular heart diseases. (3) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to paragraph (1), give priority to entities seeking to carry out projects for populations most impacted by valvular heart diseases. (4) Coordination of activities The Secretary shall, as appropriate, ensure that activities under this section are coordinated with other agencies and offices of the Department of Health and Human Services that carry out activities regarding valvular heart diseases. (5) Best practices The Secretary shall, as applicable and appropriate, identify and disseminate best practices for relevant health care providers related to valvular heart diseases. (d) Authorization of appropriations For purposes of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2023 through 2027.

July 12, 2022 Reported with an amendment

tv_txt: 117th CONGRESS 2d Session H.R. 1193 In the Senate of the United States, December 1, 2022. Amendment:

That the bill from the House of Representatives (H.R. 1193) entitled An Act to amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes. , do pass with the following Strike all after the enacting clause and insert the following: 1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act . 2. HHS valvular heart disease activities (a) In general The Secretary of Health and Human Services (referred to in this section as the Secretary ) shall, as appropriate, continue activities related to research, education, and awareness of valvular heart diseases. (b) NIH research related to valvular heart diseases (1) In general The Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, may support or conduct research regarding valvular heart diseases. (2) Support further research In order to improve information on, and understanding of, causation and risk factors for valvular heart diseases, research conducted or supported under this subsection for such diseases may include the following: (A) Use of advanced technological imaging and other relevant methods to generate data related to valvular heart diseases. (B) Assessing potential risk factors for sudden cardiac arrest or sudden cardiac death from valvular heart diseases. (C) Other activities, as appropriate, in order to improve the availability of information on, and advance research related to, valvular heart diseases. (3) Mitral valve prolapse workshop Not later than 2 years after the date of enactment of this Act, the Director of the National Heart, Lung, and Blood Institute shall, as appropriate, convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop recommendations for the identification and treatment of individuals with mitral valve prolapse, including such individuals who may be at risk for sudden cardiac arrest or sudden cardiac death. (c) Prevention activities to improve awareness of sudden cardiac death as a result of valvular heart diseases (1) In general The Secretary may carry out activities to increase education and awareness of valvular heart diseases in order to reduce the incidence of sudden cardiac death caused by such diseases. The Secretary may— (A) award grants or contracts to public or nonprofit private entities to carry out activities under this subsection; and (B) directly, or through grants or contracts, provide technical assistance with respect to such activities. (2) Certain activities Upon availability of applicable data, projects carried out under paragraph (1) may include— (A) continuing activities at the Centers for Disease Control and Prevention related to valvular heart diseases; (B) improving the awareness of the public concerning any risk factors for, the symptoms of, and the public health impact of, valvular heart diseases; and (C) enhancing public health data collection and improving the quality of such data, as appropriate, regarding cardiac arrests, including cardiac arrests that occur outside of the hospital. (3) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to paragraph (1), give priority to entities seeking to carry out projects for populations most impacted by valvular heart diseases. (4) Coordination of activities The Secretary shall, as appropriate, ensure that activities under this section are coordinated with other agencies and offices of the Department of Health and Human Services that carry out activities regarding valvular heart diseases. (5) Best practices The Secretary shall, as applicable and appropriate, identify and disseminate best practices for relevant health care providers related to valvular heart diseases. (d) Authorization of appropriations For purposes of carrying out this section, there are authorized to be appropriated $28,000,000 for each of fiscal years 2023 through 2027.

Secretary

tv_txt: I One Hundred Seventeenth Congress of the United States of America At the Second Session Begun and held at the City of Washington on Monday, the third day of January, two thousand and twenty-two H. R. 1193 AN ACT To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act . 2. HHS valvular heart disease activities (a) In general The Secretary of Health and Human Services (referred to in this section as the Secretary ) shall, as appropriate, continue activities related to research, education, and awareness of valvular heart diseases. (b) NIH research related to valvular heart diseases (1) In general The Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, may support or conduct research regarding valvular heart diseases. (2) Support further research In order to improve information on, and understanding of, causation and risk factors for valvular heart diseases, research conducted or supported under this subsection for such diseases may include the following: (A) Use of advanced technological imaging and other relevant methods to generate data related to valvular heart diseases. (B) Assessing potential risk factors for sudden cardiac arrest or sudden cardiac death from valvular heart diseases. (C) Other activities, as appropriate, in order to improve the availability of information on, and advance research related to, valvular heart diseases. (3) Mitral valve prolapse workshop Not later than 2 years after the date of enactment of this Act, the Director of the National Heart, Lung, and Blood Institute shall, as appropriate, convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop recommendations for the identification and treatment of individuals with mitral valve prolapse, including such individuals who may be at risk for sudden cardiac arrest or sudden cardiac death. (c) Prevention activities to improve awareness of sudden cardiac death as a result of valvular heart diseases (1) In general The Secretary may carry out activities to increase education and awareness of valvular heart diseases in order to reduce the incidence of sudden cardiac death caused by such diseases. The Secretary may— (A) award grants or contracts to public or nonprofit private entities to carry out activities under this subsection; and (B) directly, or through grants or contracts, provide technical assistance with respect to such activities. (2) Certain activities Upon availability of applicable data, projects carried out under paragraph (1) may include— (A) continuing activities at the Centers for Disease Control and Prevention related to valvular heart diseases; (B) improving the awareness of the public concerning any risk factors for, the symptoms of, and the public health impact of, valvular heart diseases; and (C) enhancing public health data collection and improving the quality of such data, as appropriate, regarding cardiac arrests, including cardiac arrests that occur outside of the hospital. (3) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to paragraph (1), give priority to entities seeking to carry out projects for populations most impacted by valvular heart diseases. (4) Coordination of activities The Secretary shall, as appropriate, ensure that activities under this section are coordinated with other agencies and offices of the Department of Health and Human Services that carry out activities regarding valvular heart diseases. (5) Best practices The Secretary shall, as applicable and appropriate, identify and disseminate best practices for relevant health care providers related to valvular heart diseases. (d) Authorization of appropriations For purposes of carrying out this section, there are authorized to be appropriated $28,000,000 for each of fiscal years 2023 through 2027.

Speaker of the House of Representatives. Vice President of the United States and President of the Senate.